95 results about "Aerodynamic diameter" patented technology

The invention describes novel dried powders of peptide therapeutic agent useful for producing highly respirable aerosols and the methods for their manufacture. Insulin is the peptide therapeutic agent in the preferred embodiment. The powders of insulin prepared for pulmonary administration are characterized by the peculiar structure and shape of the microparticles that allow the powder to flow and to be easy aerosolized. Typical dry powder of insulin described in this patent show corrugated, nonagglomerated microparticles with a low tapped density. The mean geometric diameter (particle size) ranges between 1.0 and 10.0 micron and the mass median aerodynamic diameter (MMAD) ranges between 1.0 and 4.0 micron. These insulin pulmonary powders exhibit in vitro a very high respirable fraction (>75%).

An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. The composition is stabilized by using a small amount of mineral acid and a suitable can having part or all of its internal metallic surfaces made of stainless steel, anodized aluminium or lined with an inert organic coating.

The invention discloses an efficient low-resistance nano-fiber microscopic gradient structure filtering material and a preparation method thereof. The filtering material comprises a nanometer fine filtering layer, a micrometer support primary filtering layer and protective surface layers, wherein the micrometer support primary filtering layer and the nanometer fine filtering layer are interactively overlaid, and arranged between the two protective surface layers. The nanometer fine filtering layer has a grid structure, and the nanometer fine filtering layer is composed of a plane matrix fiberlayer and cone structures, wherein fibers between the tips of the cone structures and a grid matrix fiber layer have an oriented structure along the tips and the plane matrix fiber layer. By means ofthe filtering material without electricity, the efficiency of filtering NaCl aerosol with the mass median aerodynamic diameter of 0.26 micrometer is 99.9-99.999%, and the pressure is reduced to 130-300 Pa; by means of the filtering material which is treated by electricity, the efficiency of filtering the NaCl aerosol with the mass median aerodynamic diameter of 0.26 micrometer is 99.9-99.999%, andthe pressure is reduced to 30-250 Pa.

A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having a mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline and nebulized into an aerosol having a mass median aerodynamic diameter 3 μm to 10 μm and a geometric standard deviation less than 1.7 using an electronic nebulizer.

A composition is provided for administration to a subject by way of a needleless syringe. The composition is formed from particles having a mean mass aerodynamic diameter of from 1 to 250 microns, and an envelope density of from 0.1 to 25 g / cm.sup.3, where the particles include a biologically active agent and a sustained-release material that controls release of the active agent to a subject following administration of the composition thereto. Methods for delivering a biologically active agent to a subject are also provided.